A growing body of evidence demonstrates the importance of walking limitations in multiple sclerosis (MS). At the same time, there is increasing pressure on health care providers to monitor the outcomes of their interventions. Owing to its impact on our patients' functional status, quality of life, and health, walking appears as an essential parameter to measure and follow over time. However, there are practical obstacles and still unanswered questions regarding the measurement of walking in the management of MS.
Pros and Cons of Routine Measurement of Walking in a Clinical Setting
There are many reasons to monitor walking in MS patients. Worsening of walking performance may be a sign of disease activity, which is an important consideration in the management of disease-modifying therapies (especially when taking into account the recently introduced concept of 'disease activity-free status'). One study in progressive MS patients found that change in walking speed was significantly related to long-term (after 5 years of more) self-reported impact of the disease and self-reported walking limitations. 6 Since it is established that walking represents a significant component of MS-related disability, change in walking performance can be useful in assessing the need for other interventions, such as symptomatic therapies, rehabilitation, and support services. Furthermore, walking is a meaningful parameter to follow in assessing the efficacy of these interventions, or potential side effects of various treatments (e.g. increased weakness from symptomatic medications for spasticity).
However, potential obstacles should not be ignored. which compare favorably to traditional clinician-driven testing.
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Conclusion
Lessons can be learned from other clinical populations. In the elderly, walking speed has been proposed as the 'sixth vital sign,' 11 based on its correlation with concomitant and future functional and health outcomes.
In MS, accumulating evidence, and the availability of user-friendly validated measurement tools, build a case for integrating quantitative monitoring of walking into the routine comprehensive care of our patients.
Undoubtedly, obstacles remain, and important questions still need to be answered. However, large-scale 'real world' use of these tools will also help address these concerns, to the ultimate benefit of our patients and their loved ones. And we should not forget other aspects of mobility inside and outside the home environment (e.g. wheelchair mobility, driving, use of public transportation), particularly in patients who have lost the ability to walk. n
